retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial Efficacy and safety of retatrutide, a GIP, GLP-1, and receptor agonist, in people with type diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Retatrutide for Obesity: Phase 2

A previous study has established that the BV-2 cell line derived from microglia can secrete GLP-1 and that GLP-1 secretion is reduced under inflammatory stimulation [107], suggesting a potential autocrine or paracrine role for GLP-1 signaling within microglia

doi:10.1136/bmj.k872

These medications work gradually, and people see the best results in coordination with lifestyle changes and a reduced-calorie diet

The brain physiology entails simplification of some aspects of the occupancy calculation, which are not validated in peripheral tissue such as here

98.Dong N, Zhu C, Jiang J, Huang D, Li X, Quan G, et al

That plan includes a reduced-calorie diet and consistent movement goals